欢迎访问《现代生物医学进展》编辑部！

目的：探讨恩替卡韦治疗HBeAg 阳性乙型肝炎的疗效与安全性。方法：140 例慢性乙肝患者随机分为2 组：观察组予恩替卡韦0.5 mg/d，对照组予拉米夫定100 mg/d，疗程均为48 周。观察两组HBV DNA 阴转率、ALT 复常率、HbeAg 血清转换率以及不良反应发生情况。结果：在治疗12 周后，观察组与对照组HBV DNA 阴转率分别为47.1%、22.9% (P<0.01)，ALT 复常率分别为 51.4%、31.4% (P<0.05)，在治疗48 周后，观察组与对照组HBV DNA 阴转率分别为88.6%、48.6% (P<0.01)，ALT 复常率分别为 90.0%、72.9% (P<0.01)。HbeAg 血清转换率无统计学差异，两组患者未见严重不良反应。结论：恩替卡韦治疗HBeAg 阳性乙肝患者，较拉米夫定起效快、作用强，且安全性好。

英文摘要:

Objective: To investigate efficacy and safety of entecavir on treatment of hepatitis B with positive HBeAg. Methods: 140 patients with chronic hepatitis B were randomly divided into 2 groups: study group were treated with entecavir 0.5 mg/d, and the control group were given lamivudine 100 mg/d. Both of the course was 48 weeks. HBV DNA negative conversion rates, ALT normalization rate, HBeAg seroconversion rates and incidence of adverse reactions were observed. Results: After 12 weeks of treatment, HBV DNA negative conversion rate of the observation and control group were 47.1% and 22.9% (P <0.01), respectively. ALT normalization rate were 51.4% and 31.4% (P <0.05), respectively. After 48 weeks of treatment, HBV DNA negative conversion rate of the observation and control group were 88.6% and 48.6% (P <0.01), respectively. ALT normalization rate were 90.0% and 72.9% (P <0.01), respectively. HBeAg seroconversion between the two groups were no significant difference. No serious adverse events occurred in the both groups. Conclusion: Compared with lamivudine, entecavir shows more rapid onset, stronger efficacy, and safety on treatment of hepatitis B with positive HBeAg.

View Full Text View/Add Comment Download reader